Table 1 Characteristics of clinical, immunological, and virological parameters, and antiretroviral treatment of vertically HIV-1-infected children.
Previous-ART | |
|---|---|
N. of HIV-children | 42 |
Age (years) (a) | 6.7 ± 0.64 (0.5; 16.1) |
Male (b) | 16 (38.1%) |
AIDS diagnosis (CDC) (b) | 23 (54.7%) |
Baseline CD4 + cell count | |
% CD4+(a) | 23.2 ± 1.8 (0.8; 49.7) |
15 – 25% CD4+(b) | 13 (22%) |
<15 % CD4+(b) | 16 (27.1%) |
Baseline HIV-RNA level | |
log10 VL (copies/mL)(a) | 4.52 ± 0.11 (3.22; 6.84) |
VL >50,000 copies/mL(b) | 14 (33.3%) |
ART with NRTI prior-HAART (b) | |
Monotherapy | 39 (92.9%) |
Therapy combined | 3 (7.1%) |
HAART regimen at baseline (b) | |
3TC + d4T + NFV | 27 (64.3%) |
AZT + 3TC + NFV | 6 (14.3%) |
d4T + ddI + NFV | 9 (21.49%) |
New NRTI on HAART | |
0 NRTI | 14 (33.3%) |
1 NRTI | 14 (33.3%) |
2 NRTI | 14 (33.3%) |
HAART regimen during follow-up (b) | |
Global adherence (>90%) | 100% |
Change of drugs on first line of HAART | 9 (21.4%) |
Change of NRTI | 2 (4.8%) |
Adding a NNRTI | 4 (9.5%) |
Adding a PI | 3 (7.1%) |
Stop of HAART with NFV | 16 (38.1%) |
Change of NFV by other PI | 12 (28.6%) |
Interruption of HAART | 4 (9.5%) |